



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	09/731,872
Filing Date	December 7, 2000
First Named Inventor	J-B Dumas Milne Edwards
Examiner Name	Chih Min Kam
Group Art Unit	1653
Attorney Docket No.	G-078US03R

METHOD OF PAYMENT

FEE CALCULATION (continued)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 19-0065

Deposit Account Name: Saliwanchik, Lloyd & Saliwanchik

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	FEE PAID
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$ 0.00)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from Below	Fee Paid
<input type="checkbox"/>	-20** = <input type="checkbox"/>	X <input type="checkbox"/>	= <input type="checkbox"/>
Independent Claims <input type="checkbox"/>	-3** = <input type="checkbox"/>	X <input type="checkbox"/>	= <input type="checkbox"/>
Multiple Dependent <input type="checkbox"/>		<input type="checkbox"/>	= <input type="checkbox"/>

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00)

**or number previously paid, if greater; For Reissues, see above.

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Fee Code	Small Entity Fee (\$)	Fee Description
105	130	205	65	Surcharge-late filing fee or oath
127	50	227	25	Surcharge-late provisional filing fee or cover sheet
139	130	139	130	Non-English specification
147	2,520	147	2,520	For filing a request for ex parte reexamination
112	920*	112	920*	Requesting publication of SIR prior to Examiner action
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
115	110	215	55	Extension for reply within first Month
116	400	216	200	Extension for reply within second month
117	920	217	460	Extension for reply within third month
118	1,440	218	720	Extension for reply within fourth month
128	1,960	228	980	Extension for reply within fifth month
119	320	219	160	Notice of Appeal
120	320	220	160	Filing for a brief support of an appeal
121	280	221	140	Request for oral hearing
138	1,510	138	1,510	Petition to institute a public use proceeding
140	110	240	55	Petition to revive-unavoidable
141	1,280	241	640	Petition to revive-unintentional
142	1,280	242	640	Utility issue fee (or reissue)
143	460	243	230	Design issue fee
144	620	244	310	Plant issue fee
122	130	122	130	Petitions to the Commissioner
123	50	123	50	Processing fee under 37 CFR 1.17(q)
126	180	126	180	Submission of Information Disclosure Stmt.
581	40	581	40	Recording each patent assignment per property (times number of properties)
146	740	246	370	Filing a submission after final rejection (37 CFR §1.129(a))
149	740	249	370	For each additional invention to be examined (37 CFR§1.129(b))
179	740	279	370	Request for Continued Examination (RCE)
169	900	169	900	Request for expedited examination of a design application

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)


SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Frank C. Eisenschenk, Ph.D.	Registration No. (Attorney/Agent)	45,332	Telephone	352-375-8100
Signature	<i>Frank C. Eisenschenk</i>	Date	December 24, 2002		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on December 24, 2002.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

#14
1-803
201653/11
INFORMATION DISCLOSURE STATEMENT
Examining Group 1653
Patent Application
Docket No. G-078US03REG
Serial No. 09/731,872

RECEIVED
JAN 02 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Chih Min Kam
Art Unit : 1653
Applicant(s) : Jean-Baptiste Dumas Milne Edwards *et al.*
Serial No. : 09/731,872
Filed : December 7, 2000
For : Full-Length Human cDNAs Encoding Potentially Secreted Proteins

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first office action on the merits, but before the mailing of a final action or the notice of allowance.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

A Fee Transmittal Sheet, in duplicate, is enclosed for the \$180 surcharge for this submission. The Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

A Professional Association

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

FCE/jaj

Attachments: Form PTO/SB/08A & B (3 pages)
Fee Transmittal Form (in duplicate)
Copies of references cited (21) – **including 1 on CD-ROM**

RECEIVED
JAN 02 2003FACILITY CENTER 1600/2900
PTO/SB/08A (10-01)Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/731,872
				Filing Date	12/7/2000
				First Named Inventor	J.-B. Dumas Milne Edwards
				Art Unit	1653
				Examiner Name	Chih Min Kam
Sheet	1	of	3	Attorney Docket Number	G-078US03REG

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	EP	1130094 A2 (CD-ROM)	07/07/2000	Helix Research Institute	
	F2	WO	98/55614 A2	12/10/1998	Genetics Institute, Inc.	
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

⊕ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	09/731,872
Filing Date	12/7/2000
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1653
Examiner Name	Chih Min Kam
Attorney Docket Number	G-078US03REG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BOUGUELERET, L. <i>et al.</i> , "Extended cDNAs useful for expressing secreted proteins and to obtain specific antibodies", 2000, pp. 203-204, Accession No. AAY59685.	
	R2	CAMERON, C. <i>et al.</i> , "Function and Protective Capacity of <i>Treponema pallidum</i> subsp. <i>pallidum</i> Glycerophosphodiester Phosphodiesterase", <i>Infection and Immunity</i> (1998), pp. 5763-5770, Vol. 66, No. 12, American Society for Microbiology.	
	R3	DOWNES, G. <i>et al.</i> , "Structure and Mapping of the G Protein $\gamma 3$ Subunit Gene and a Divergently Transcribed Novel Gene, <i>Gng31g</i> ", <i>Genomics</i> (1998), pp. 220-230, Vol. 53, Academic Press.	
	R4	INOUE, S. <i>et al.</i> , "Growth Suppression of <i>Escherichia coli</i> by Induction of Expression of Mammalian Genes with Transmembrane or ATPase Domains", <i>Biochem. Biosphys. Reas. Comm.</i> (2000), pp. 553-561, Vol. 268, Academic Press.	
	R5	JANSON, H., <i>et al.</i> , "Protein D, the Glycerophosphodiester Phosphodiesterase from <i>Haemophilus influenzae</i> with Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model", <i>Infection and Immunity</i> , 1994, pp. 4848-4854, Vol. 62, No. 11, American Society for Microbiology.	
	R6	LARSON, T., <i>et al.</i> , "Periplasmic Glycerophosphodiester Phosphodiesterase of <i>Escherichia coli</i> , a New Enzyme of the <i>glp</i> Regulon", <i>J. Biol. Chem.</i> , 1983, pp. 5428-5432, Vol. 258, No. 9.	
	R7	MAGRÉ, J. <i>et al.</i> , "Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13", <i>Nature Genetics</i> (2001), pp. 365-370, Vol. 28.	
	R8	MELDRUM, Brian, "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", <i>The Journal of Nutrition - Supplement</i> (presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences.	
	R9	MUNSON, R. <i>et al.</i> , "Protein D, a Putative Immunoglobulin D-Binding Protein Produced by <i>Haemophilus influenzae</i> , Is Glycerophosphodiester Phosphodiesterase", <i>J. Bacteriology</i> , 1993, pp. 4569-4571, Vol. 175, No. 14.	
	R10	NEER, Eva, "Heterotrimeric G Proteins: Organizers of Transmembrane Signals", <i>Cell</i> , 1995, pp. 249-257, Vol. 80, Cell Press.	
	R11	SCHOEPP, D. <i>et al.</i> , "Metabotropic glutamate receptors in brain function and pathology", <i>TIPS</i> , 1993, pp. 13-20, Vol. 14, Elsevier Science Publishers, Ltd., UK.	
	R12	ZHENG, B. <i>et al.</i> , "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>PNAS</i> , 2000, pp. 3999-4004, Vol. 97, No. 8.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
JAN 02 2003
TECH CENTER 1600/2900
+

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/731,872
				Filing Date	12/7/2000
				First Named Inventor	J.-B. Dumas Milne Edwards
				Group Art Unit	1653
				Examiner Name	Chih Min Kam
				Attorney Docket Number	G-078US03REG
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AAF65234 (bases 1 to 331).	<input checked="" type="checkbox"/>
	R14	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200).	<input checked="" type="checkbox"/>
	R15	Glycerophosphoryl Diester Phosphodiesterase <i>Escherichia coli</i> (1989), NiceProt View of SWISS-PROT: P10908.	<input checked="" type="checkbox"/>
	R16	Glycerophosphoryl Diester Phosphodiesterase, periplasmic [Precursor] <i>Escherichia coli</i> (1991), NiceProt View of SWISS-PROT: P09394.	<input checked="" type="checkbox"/>
	R17	Glycerophosphoryl Diester Phosphodiesterase [Precursor] <i>Haemophilus influenzae</i> (1995), NiceProt View of SWISS-PROT: Q06282.	<input checked="" type="checkbox"/>
	R18	Similar to G Protein Gamma 3 Linked Gene <i>Homo Sapiens</i> (2001), NiceProt View of SWISS-PROT: Q9BSQ0.	<input checked="" type="checkbox"/>
	R19	Hypothetical 43.1 kDa protein <i>Mus musculus</i> (2000), NiceProt View of SWISS-PROT: Q9JMF1.	<input checked="" type="checkbox"/>
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.